Literature DB >> 32582513

A case of advanced gastric cancer showing HER2 positivity after chemotherapy.

Suguru Hirose1, Toshikazu Moriwaki1, Masamichi Yamaura1, Daisuke Suganuma1, Hiroki Tajima1, Masashi Sato1, Chiaki Enami1, Takeshi Yamada1, Yoshiyuki Yamamoto1, Noriaki Sakamoto2, Ichinosuke Hyodo1.   

Abstract

A 63-year-old man had advanced poorly differentiated gastric adenocarcinoma with para-aortic lymph node metastases. No HER2 expression was observed in four endoscopic biopsies from the primary tumor. Tumors shrunk after S-1 with cisplatin treatment, and he underwent simple gastrectomy due to stenosis. Interestingly, HER2 diffusely overexpressed in the resected surgical specimen. His disease was stable with trastuzumab-containing therapy for 6.4 months. This case may suggest a selection of HER2-positive cells that were insensitive to the chemotherapy, and further study is needed for the change of intratumoral HER2 heterogeneity after chemotherapy. © The Japan Society of Clinical Oncology 2020.

Entities:  

Keywords:  Biopsy; Epidermal growth factor receptor-2; Gastric cancer; Heterogeneity; Trastuzumab

Year:  2020        PMID： 32582513      PMCID： PMC7297895          DOI： 10.1007/s13691-020-00412-8

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN： 2192-3183


  21 in total

1.  Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.

Authors:  Yuji Mishima; Satoshi Matsusaka; Keisho Chin; Mariko Mikuniya; Sayuri Minowa; Tomoko Takayama; Harumi Shibata; Ryoko Kuniyoshi; Mariko Ogura; Yasuhito Terui; Nobuyuki Mizunuma; Kiyohiko Hatake
Journal:  Target Oncol       Date:  2017-06       Impact factor: 4.493

2.  Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.

Authors:  Jiyuan Yang; Hesheng Luo; Yan Li; Junchuan Li; Zhiqiang Cai; Xiaoyan Su; Danqing Dai; Wei Du; Tingxuan Chen; Ming Chen
Journal:  Cell Biochem Biophys       Date:  2012-01       Impact factor: 2.194

3.  Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.

Authors:  Hee Eun Lee; Kyoung Un Park; Seol Bong Yoo; Soo Kyung Nam; Do Joong Park; Hyung-Ho Kim; Hye Seung Lee
Journal:  Eur J Cancer       Date:  2012-11-09       Impact factor: 9.162

4.  Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

Authors:  Y Y Janjigian; D Werner; C Pauligk; K Steinmetz; D P Kelsen; E Jäger; H M Altmannsberger; E Robinson; L J Tafe; L H Tang; M A Shah; S-E Al-Batran
Journal:  Ann Oncol       Date:  2012-06-11       Impact factor: 32.976

5.  Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.

Authors:  Stephen Lee; Willem Bastiaan de Boer; Soraya Fermoyle; Michael Platten; Marian Priyanthi Kumarasinghe
Journal:  Histopathology       Date:  2011-11       Impact factor: 5.087

Review 6.  The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

Authors:  J S Ross; J A Fletcher
Journal:  Stem Cells       Date:  1998       Impact factor: 6.277

7.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Yoon-Koo Kang; Narikazu Boku; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Li-Tzong Chen
Journal:  Lancet       Date:  2017-10-06       Impact factor: 79.321

8.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

9.  Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.

Authors:  Hiroshi Yoshida; Noriko Yamamoto; Hirokazu Taniguchi; Ichiro Oda; Hitoshi Katai; Ryoji Kushima; Hitoshi Tsuda
Journal:  Virchows Arch       Date:  2014-06-03       Impact factor: 4.064

10.  Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.

Authors:  V S Warneke; H-M Behrens; C Böger; T Becker; F Lordick; M P A Ebert; C Röcken
Journal:  Ann Oncol       Date:  2012-11-08       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.